Doximity, Inc.

Doximity, Inc. (DOCS) Market Cap

Doximity, Inc. has a market capitalization of $3.85B.

Price: $20.59

-0.11 (-0.53%)

Market Cap: 3.85B

NYSE · time unavailable

CEO: Jeffrey A. Tangney

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2021-06-24

Website: https://www.doximity.com

Doximity, Inc. (DOCS) - Company Information

Market Cap: 3.85B|Sector: Healthcare

Company Profile

Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.

Analyst Sentiment

78%
Strong Buy

From 23 Active Polls

1Y Forecast: $29.47

▲ +43.1% Potential Upside

Consensus Target Metrics

Low Bound

$18

Median

$26

High Bound

$59

Average

$29

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$29.47
▲ +43.13% Upside
Low Target
$18.00
-13% Risk
Median Target
$26.00
26% Mid
High Target
$59.00
187% Max
Consensus
Hold
10 / 23 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)3,8514,3078,30214,64411,53110,9319,9938,1155,099
Enterprise Value ($M)3,6424,0988,24714,48611,40610,7339,8407,9445,001
Price to Earnings Ratio (P/E)19.4156.3333.7158.9954.0643.7533.2245.9530.81
Price/Earnings-to-Growth Ratio (PEG)3.443.819.811.435.734.22
Price to Sales Ratio (P/S)5.9729.6344.8686.8979.0379.0459.2759.3140.25
Price to Book Ratio (P/B)4.004.538.4813.3711.2410.109.698.445.58
Price to Free Cash Flow Ratio (P/FCF)12.1340.15141.87159.91191.75112.71157.57121.48128.95
Enterprise Value to Sales (EV/Sales)28.1944.5785.9678.1777.6258.3658.0639.48
Enterprise Value to EBITDA (EV/EBITDA)14.82165.07108.68185.46170.38208.38119.16136.83102.88
Debt to Equity Ratio-0.850.010.010.010.010.010.010.010.02

DOCS Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$20.59
Intrinsic Value$23.58
Market Alignment
Undervalued by 14.5%relative to calculated intrinsic value
9.00%
Exp: 9%9%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2036)

Terminal FCF Base$0.39B
Perpetuity TV Value$7.25B
Discounted TV (PV)$2.81B
TV Weighting %60.4%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 DOXIMITY INC CLASS A (DOCS) — Investment Overview

🧩 Business Model Overview

Doximity operates a U.S.-focused professional network for physicians built around identity verification and workflow-oriented communication tools. The platform connects health systems and life-sciences stakeholders with a large, engaged base of verified clinicians through patient- and physician-facing channels (where applicable), direct messaging, and engagement products designed to fit into day-to-day physician routines.

A key element of the value chain is the two-sided demand dynamic: physicians receive utility through a trusted professional environment, while advertisers and commercial life-sciences customers (pharma, devices, and related services) pay for access to, and targeting within, that physician base. This structure creates durable retention on the physician side and improves monetization efficiency on the commercial side as targeting and response rates improve.

💰 Revenue Streams & Monetisation Model

Revenue is primarily driven by recurring and usage-linked offerings tied to ongoing physician engagement and sustained marketing/information needs of life-sciences customers. Monetisation typically includes:

  • Business-to-consumer subscription/engagement features: Physician-facing subscriptions and premium functionality that deepen daily usage and broaden retention.
  • Business-to-business advertising and promotion: Sponsorships, promoted placements, and targeted campaigns that monetize the attention and reach of the physician network.
  • Performance and lead-generation economics: Products designed to drive measurable outcomes for commercial clients, where pricing can be linked to campaign effectiveness.

Margin structure tends to benefit from software-like economics—incremental distribution costs are limited once the physician platform and data infrastructure are in place—while the principal drivers of profitability are (i) sales efficiency, (ii) network engagement intensity, and (iii) ability to maintain high targeting quality that supports client willingness-to-pay.

🧠 Competitive Advantages & Market Positioning

The competitive moat is best characterized as high switching costs (data gravity + workflow integration) paired with network effects among verified physicians.

  • Switching costs / Data gravity: Physician participation and engagement generate a proprietary understanding of user identity, specialty distribution, and interaction patterns. Commercial targeting improves as the platform’s data and usage context become more entrenched, making it harder for customers to replicate comparable reach and performance elsewhere.
  • Network effects: As physician adoption rises, Doximity becomes a more valuable channel for life-sciences marketers seeking dense access to specific specialties and geographies, improving the platform’s ROI for advertisers and reinforcing physician usage.
  • Identity trust and professional verification: Verified profiles and governance around clinician identity reduce waste for marketers and support credibility with physicians—an advantage that is difficult to rebuild at scale.

Competitive benchmarking (primary alternatives):

  • Sermo: Competes for physician community engagement and advertising inventory. Sermo is more community-led, while Doximity’s positioning places heavier emphasis on workflow-adjacent tools and verified identity to support conversion-oriented marketing.
  • Medscape (via WebMD professional network): Competes through editorial content and physician engagement with pharmaceutical advertising. Medscape’s strength is content distribution; Doximity’s differentiator is the clinician network combined with interaction and targeting data that support campaign performance.
  • LinkedIn and other broad professional networks: Competes indirectly for some reach and targeting, but typically lacks the same depth of verified physician identity, specialty density, and healthcare-specific engagement layer.

Overall, Doximity’s focus is a U.S. physician network with healthcare-specific identity and engagement, rather than general professional reach or primarily content-led distribution.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, the investment case rests on secular adoption of digital channels in physician workflows and continued growth in life-sciences spend aimed at evidence-based, measurable HCP engagement. Principal growth drivers include:

  • Digitization of physician communications: Ongoing migration of routine clinical and professional communication to digital touchpoints increases the addressable inventory and engagement value of a dedicated physician network.
  • More accountable healthcare marketing: Pharma and device companies increasingly allocate budgets toward measurable targeting and attributable outcomes, benefiting platforms that can improve response rates via better identity and interaction data.
  • Telehealth and distributed care support: Expanding care delivery models increase demand for physician-facing digital coordination and information sharing—areas where a clinician network can deepen usage.
  • Product expansion across the clinician lifecycle: Additional engagement surfaces (education, recruitment/workforce tooling, and communication utilities) can extend customer lifetime value while maintaining software-like cost discipline.

TAM expansion is driven by both (i) the size of the U.S. physician population reachable through verified digital channels and (ii) the portion of life-sciences marketing that shifts from broad media to specialty-targeted performance channels.

⚠ Risk Factors to Monitor

  • Privacy, data protection, and compliance risk: Physician data handling and communications tools require robust governance. Regulatory changes and enforcement intensity can raise costs or constrain product features.
  • Regulatory and reputational scrutiny: Healthcare-adjacent platforms can face elevated scrutiny around promotional content, claims, and user protections.
  • Platform and technological disruption: Competition could emerge from telehealth workflow ecosystems, EHR-adjacent channels, or new engagement platforms that acquire distribution advantages.
  • Customer concentration and ad-cycle volatility: Demand from life-sciences customers can fluctuate with budgeting priorities, contracting cycles, and shifts in marketing strategy.
  • Cybersecurity and operational resilience: Trust is central to verified identity platforms; any breach or service degradation can impair physician adoption and advertiser confidence.

📊 Valuation & Market View

Market valuation for physician-network and software-like platforms typically centers on revenue durability, engagement-driven monetization, and margin trajectory rather than asset intensity. Investors often anchor on growth and operating efficiency metrics (e.g., revenue growth quality, contribution margin, and the scalability of sales and product costs).

Key valuation drivers commonly include:

  • Evidence of sustained physician retention and engagement (supporting recurring monetization and improved targeting)
  • Ability to expand monetization per physician without impairing trust or compliance
  • Sales efficiency and repeatability in converting life-sciences budgets into measurable campaign outcomes
  • Operating leverage as the platform scales

🔍 Investment Takeaway

Doximity’s long-term thesis rests on a structurally advantaged position in U.S. physician engagement: verified identity, dense specialty reach, and a platform that benefits from network effects and switching costs through data gravity and workflow integration. As life-sciences marketing continues shifting toward measurable, targeted HCP channels, Doximity’s ability to sustain physician participation and improve campaign performance supports a durable revenue model with software-like scalability—tempered by regulatory, privacy, and competitive execution risks.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for DOCS.

prnewswire.com2026-06-05

Did Five Below, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

prnewswire.com2026-06-04

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

globenewswire.com2026-06-02

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

businesswire.com2026-06-02

DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $DOCS--DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Investigation with the Schall Law Firm.

zacks.com2026-05-28

OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?

OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressures near-term growth.

prnewswire.com2026-05-28

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

fool.com2026-05-27

Doximity: A Strong Contender or Vulnerable to Disruption?

Curious about Doximity's potential in the evolving healthcare tech landscape? Tune in as our experts rate its business strength and future growth prospects!

globenewswire.com2026-05-26

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

fool.com2026-05-24

Doximity Stock Just Got Crushed. Is This a Rare Chance to Buy a High-Quality Growth Company on Sale?

The market seems concerned that AI could replace some of Doximity's solutions for the medical community. However, its powerful ecosystem, paired with complex regulations, shouldn't be easily disrupted.

prnewswire.com2026-05-21

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

businesswire.com2026-05-21

Doximity to Present at the William Blair 46th Annual Growth Stock Conference

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, co-founder and CEO, will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 4:40 p.m. Central Time. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians across all specialties a.

zacks.com2026-05-20

OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds

OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.

proactiveinvestors.co.uk2026-05-19

Dr Martens profits jump as turnaround gains grip

Dr Martens PLC (LSE:DOCS) returned to profit growth last year as the bootmaker tightened discounting, improved margins and pushed ahead with a turnaround centred on higher-quality sales. The FTSE 250-listed group reported an adjusted pre-tax profit of £55 million in the year to 29 March, up 61% on the year before, while revenue fell 2.9% to £764.9 million.

247wallst.com2026-05-18

Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss.

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector's short history, and bargain hunters are circling the wreckage.

247wallst.com2026-05-18

7 Healthcare AI Stocks Under $50 With Huge Upside Potential

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"DOCS reported Q4 2026 (ended 2026-03-31) revenue of $145.4M and net income of $19.1M (EPS $0.10). YoY, revenue was up ~5.1% versus Q4 2025 ($138.3M), but net income fell ~69.4% versus $62.5M. QoQ, revenue declined ~21.5% from Q3 2026 ($185.1M), and net income dropped ~68.9% from $61.6M. Profitability weakened meaningfully this quarter. Gross margin eased to ~86.7% from ~89.9% QoQ, and net margin contracted to ~13.1% from ~33.3% QoQ, indicating a sharp increase in relative costs/operating leverage reversal. Operating income also fell to $24.8M from $71.9M QoQ. Cash generation remained positive: operating cash flow was $109.5M and free cash flow was $109.5M, providing strong liquidity (cash + short-term investments of ~$748.6M; net debt of ~$-209.0M, i.e., net cash). Share repurchases were modest ($2.1M) and there were no dividends. Total shareholder returns appear pressured: the stock is down 1Y (~-53.2%) with no dividend support. Despite strong balance-sheet liquidity, the earnings deterioration and weakening margins reduce near-term momentum. Analyst consensus price target implies upside versus the ~$24.71 price, but sentiment is likely cautious."

Revenue Growth

Caution

QoQ revenue declined ~21.5% (from $185.1M to $145.4M) while YoY revenue rose ~5.1% (vs. $138.3M). The latest quarter shows decelerating demand/trend consistency.

Profitability

Neutral

Net income fell ~68.9% QoQ and ~69.4% YoY. Net margin contracted to ~13.1% from ~33.3% QoQ and ~45.2% YoY; gross margin also eased (to ~86.7%).

Cash Flow Quality

Positive

Operating cash flow was $109.5M and free cash flow was $109.5M, supporting liquidity. No dividends; buybacks were small ($2.1M), so cash flow is not yet visibly translating into sustained per-share comp.

Leverage & Balance Sheet

Good

Strong liquidity with cash + short-term investments of ~$748.6M. Net debt is negative (~-$209.0M), indicating net-cash resilience despite the earnings volatility.

Shareholder Returns

Neutral

Price performance is weak: ~-53.2% over 1Y. With 0% dividend yield and limited buybacks in the quarter, total shareholder return momentum is poor.

Analyst Sentiment & Valuation

Neutral

Consensus target ($41.86) and median ($40) are above the current price ($24.71), suggesting upside; however, the steep YoY net income decline and margin compression reduce confidence in valuation support.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Doximity delivered a solid Q4 and strong cash generation while explicitly sacrificing near-term margins to fund an “AI investment year.” Revenue rose 5% YoY to $145M; free cash flow hit a record $107M. Profitability softened: adjusted EBITDA margin fell 500 bps YoY to 45% and non-GAAP gross margin fell 200 bps to 89%, largely attributed to AI compute ramp outpacing workflow engagement growth. Engagement is accelerating meaningfully—800k+ unique quarterly active prescribers (+~30% YoY) and Pathway users tripled post-acquisition, with AI queries averaging 31 per user. Commercial traction is expanding (140 health systems; Aledade partnership; ePrescribing beta; AI Search deals with top 20 pharma), but monetization is deliberately delayed. Fiscal 2027 guidance implies ~4% revenue growth and improved EBITDA margin to 49%, while management expects AI Search to ramp in the back half due to regulatory setup and approval requirements. Market demand remains cautious under policy/macro uncertainty and shorter booking horizons.

AI IconGrowth Catalysts

  • Workflow engagement acceleration: workflow engagement reached 800,000+ unique quarterly active prescribers in Q4 (+~30% YoY)
  • Nearly half of U.S. doctors now work at hospitals that buy Doximity workflow/scheduling; AI embedded as daily-use via EHR integration
  • AI Search + Scribe adoption: Pathway acquired users tripled in 9 months; AI Search/Scribe users averaged 31 queries vs 15 in January (~2x)
  • Clinical AI suite distribution wins: 140 health systems purchased clinical AI suite (incl. 7 of top 20 hospitals)

Business Development

  • Partnership with Aledade to provide value-based care AI agents using Doximity Scribe and Clinical AI suite across its network of primary care organizations
  • Photon Health powering Doximity platform back end for ePrescribing
  • AI Search go-to-market: launched at Annual Pharma Client Summit (New York) with 40 marketing leaders from world’s largest pharma; first few AI Search deals with top 20 pharma manufacturers

AI IconFinancial Highlights

  • Q4 revenue: $145M (+5% YoY), exceeding high end of guidance
  • Q4 free cash flow: $107M (record; first 9-digit free cash flow quarter)
  • Full-year revenue: $645M (+13% YoY)
  • Adjusted EBITDA margin: 45% in Q4 vs 50% prior year period (down 500 bps YoY); primary driver stated as increased AI compute costs driven by AI usage ramp
  • Non-GAAP gross margin: 89% in Q4 vs 91% prior year period (down 200 bps YoY), driven by AI compute costs
  • Full fiscal year adjusted EBITDA margin: 55% vs 55% prior year (flat); full-year non-GAAP gross margin: 91% vs 92% prior year (down 100 bps)
  • Net revenue retention: 109% on trailing 12-month basis; top 20 customers NRR: 114%
  • AI monetization guidance stance: forecasted minimal AI revenue contribution in fiscal 2026 while enabling higher R&D/compute/marketing investment that pressures near-term margins

AI IconCapital Funding

  • Share repurchases: $91M in Q4; total FY2026 buyback value $432M vs $116M in FY2025
  • Remaining repurchase authorization: $493M as of March 31, 2026
  • Balance sheet liquidity: $749M cash, cash equivalents, and marketable securities as of end of year
  • No explicit debt level disclosed in transcript

AI IconStrategy & Ops

  • AI investment year: prioritize compute scaling and AI usage growth; R&D team: 380-person R&D fully focused on Scribe/Search AI improvements
  • Product expansion: added ePrescribing (beta participation by 1,000+ prescribers with strong uptake); ePrescribing backend powered by Photon Health
  • Clinical AI competitive differentiation: PeerCheck, integrated platform approach, and health system distribution expansion
  • AI commercialization sequencing: began selling AI Search in late April; no meaningful H1 contribution expected; ramp anticipated in fiscal back half

AI IconMarket Outlook

  • Q1 fiscal 2027 revenue guidance: $151M to $152M (~4% YoY growth at midpoint)
  • Q1 fiscal 2027 adjusted EBITDA: $68.5M to $69.5M (46% adjusted EBITDA margin)
  • Full fiscal 2027 revenue guidance: $664M to $676M (~4% YoY growth at midpoint)
  • Full fiscal 2027 adjusted EBITDA: $323M to $335M (49% adjusted EBITDA margin)
  • Fiscal 2027 profitability intent: maintain adjusted EBITDA margins in high-40s or better
  • Stock-based comp: low 20s as % of revenue in fiscal 2027; trend down starting 2028
  • Subscription booking: 65% of subscription-based revenue guidance booked by date of call

AI IconRisks & Headwinds

  • HCP digital pharma ad market soft with limited visibility; demand pressure attributed to elevated policy uncertainty and increased macro risk
  • Market growth expected modest / likely at or below 5%
  • Shorter-duration incremental buys and reduced visibility; brands seeking either innovation or lower-cost engagement options under constrained budgets
  • AI Search monetization constrained by regulatory reviews/testing (keyword + suppression word targeting; longer time to stand up first-time regulatory approvals)
  • Competitive and cost pressure in AI compute: gross margin down YoY in Q4 (200 bps) and adjusted EBITDA margin down 500 bps YoY due to AI compute ramp

Q&A: Analyst Interest

  • Topic: AI Search launch—customer AI budget appetite and 2–3 year TAM framing: Management said top-20 pharma executives showed strong AI inclination with minimum budget percentages (10%–20% of budgets) in some cases, and management views AI Search as entering a largely incremental paid-search market with multibillion-dollar TAM potential.
  • Topic: HCP marketing hesitancy and AI Search competitive/margin structure: Management linked regulatory process to first-time keyword targeting mechanics (including suppression words) and stated AI Search is condition/keyword-basket based with added insights/retargeting vs native ad-only constructs, implying a different sale and longer approval cycle, not a margin-projection number in transcript.
  • Topic: Fiscal 2027 margin build—gross margin vs OpEx and CFO implications: Management guided that gross margin headwind is primarily AI compute driven by engagement jumps, with licensing cost for journals/dx docs smaller; OpEx increases include leveled AI team costs, more AI engineers, PeerCheck investments hitting selling/marketing, and intentional brand marketing spend, while highlighting CFO Matt Sonefeldt’s platform/marketing solutions background.

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the DOCS Q4 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for DOCS.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (DOCS)

© 2026 Stock Market Info — Doximity, Inc. (DOCS) Financial Profile